New Lyme Disease Treatment Gets Lives Back to Normal
Some of the most ill people I have tried to help have been diagnosed with Lyme disease. Conventionally, the diagnostic and treatment options are not good. The difficulties with long-term antibiotic protocols include the expense, lack of insurance coverage, side-effects, potential for development of antibiotic resistance and lack of studies demonstrating efficacy. If you or someone you know suffers from it, you are all too aware of these facts.
After years of research, I now present what I believe is the most effective, and the only proven, safe solution for Lyme disease treatment offered today.
The Answer is to Treat the Cause of Lyme Disease
In 1982, Dr. Willy Burgdorfer was the first scientist to discover the organism that causes it. This tick-borne spirochete was aptly named Borrelia burgdorferi. In 1995, Dr. Willy Burgdorfer performed multiple studies to determine the most effective agent for killing Borrelia burgdorferi. He proved that the most effective agent was not an antibiotic, it was silver.
In Dr. Willy Burgdorfer’s Rocky Mountain Labs study, it was demonstrated that no live spirochetes of Borrelia burgdorferi survived after 24 hours of exposure to silver in concentrations of 15 ppm and 150 ppm.” Schuan, Tom, Ph.D., Burgdorfer, Willy Ph.D. Department of Health and Human Services, National Institutes of Health, Rocky Mountain Laboratories, January, 13, 1995.
University Study Shows ACS 200 Kills Borrelia burgdorferi in 8 minutes
Building on Dr. Willy Burgdorfer’s original research, Results RNA® commissioned a major western university to test ACS 200 Extra Strength against Borrelia burgdorferi using Dr. Willy Burgdorfer’s original testing protocols. After one year of extensive research, conclusive data demonstrates that ACS 200 Extra Strength achieves complete kill against Borrelia burgdorferi in just eight (8) minutes.
Based on these results, ACS 200 is 180 times more effective than the colloidal silver used by Dr. Willy Burgdorfer in his original Lyme study.
ACS 200 is the only antimicrobial proven to kill Borrelia burgdoferi.
This research is truly astounding! Imagine using a proven, safe product that actually works! Imagine getting your health and your life back…
How Do I Purchase These Products?
Results RNA® distributes their products through licensed, health care practitioners. If you are currently seeing an Integrative Medical Practitioner, I strongly urge you to recommend incorporating ACS 200 and ACZ nano into their clinical practice on your behalf. You may also contact Results RNA® directly and they will help you locate a prescribing practitioner in your area. Results RNA® products are also available from many clinic and natural pharmacy websites online.
This data provides the scientific basis for using ACS 200 Extra Strength as an effective Lyme disease treatment. In the clinical setting, many practitioners currently prescribe ACS 200 Extra Strength to their patients with excellent outcomes. Adding Advanced Cellular Zeolite (ACZ) nano to reduce toxic body burden of toxic heavy metals is also crucial to achieving complete recovery. When taken together, ACS 200 and ACZ nano are highly effective treatments.
Are You a Doctor?
View additional research here
About the Author
Dr. Hanshew practiced medicine in the Seattle area for 15 years. She achieved Board-Certified in Family Medicine and Bariatric Medicine. She also has specialized training in Anti-Aging Medicine, Natural Hormone Replacement and Environmental Toxicity issues relating to the exponential rise in the incidence and successful treatment of Lyme disease, Autism, Fibromyalgia, ADD, Chronic Fatigue, Multiple Sclerosis, Obesity, Anxiety, Depression and Cancer.
1. Burgdorfer, William. “From Penicillin to Mild Silver Protein-An Answer to Lyme Disease Without Antibiotics”. Rocky Mountain Labortories, Division of N.I.H.
2. Cairns V, Godwin J (2005). “Post-Lyme borreliosis syndrome: a meta-analysis of reported symptoms”. Int J Epidemiol 34 (6): 1340–1345.
3. Singh SK, Girschick HJ (July 2004). “Lyme borreliosis: from infection to autoimmunity”. Clin. Microbiol. Infect. 10 (7): 598–614.
4. Stricker RB (July 2007). “Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease”. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 45 (2): 149–57.
5. Klempner MS, Hu LT, Evans J, et al. (July 2001). “Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease”. N. Engl. J. Med. 345 (2): 85–92.
6. Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, Slavov I, Cheng J, Dobkin J, Nelson DR, Sackeim HA (March 2008). “A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy”. Neurology 70 (13): 992–1003.
7. Krupp LB, Hyman LG, Grimson R, et al. (24 June 2003). “Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial”. Neurology 60 (12): 1923–30.
8. Feder HM, Johnson BJ, O’Connell S, et al. (October 2007). “A critical appraisal of “chronic Lyme disease””. N. Engl. J. Med. 357 (14): 1422–30.
9. Steere AC, Sikand VK, Schoen RT, Nowakowski J (2003). “Asymptomatic infection with Borrelia burgdorferi”. Clin. Infect. Dis. 37 (4): 528–532.
10. Fahrer H, Sauvain MJ, Zhioua E, Van Hoecke C, Gern LE (1998). “Longterm survey (7 years) in a population at risk for Lyme borreliosis: what happens to the seropositive individuals?”. Eur. J. Epidemiol. 14 (2): 117–123.
11. Smith RP, Schoen RT, Rahn DW, Sikand VK, Nowakowski J, Parenti DL, Holman MS, Persing DH, Steere AC (March 2002). “Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed erythema migrans”. Ann. Intern. Med. 136 (6): 421–428.
12. Auwaerter PG, Aucott J, Dumler JS (January 2004). “Lyme borreliosis: molecular and cellular pathobiology and prospects for prevention, diagnosis and treatment”. Expert Rev Mol Med 6 (2): 1–22.
13. Steere AC, Dhar A, Hernandez J, et al. (January 2003). “Systemic symptoms without erythema migrans as the presenting picture of early Lyme disease”. Am. J. Med. 114 (1): 58–62.
14. Dandache P, Nadelman RB (June 2008). “Erythema migrans”. Infect. Dis. Clin. North Am. 22 (2): 235–60.Stanek G, Strle F (June 2008). “Lyme disease: European perspective”. Infect. Dis. Clin. North Am. 22 (2): 327–39.
15. Chabria SB, Lawrason J (2007). “Altered mental status, an unusual manifestation of early Disseminated Lyme disease: A case report”. Journal of Medical Case Reports 1 (1): 62.
16. Shadick NA, Phillips CB, Sangha O, et al. (December 1999). “Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease”. Ann. Intern. Med. 131 (12): 919–26.
17. Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED (February 2000). “Long-term outcomes of persons with Lyme disease”. JAMA 283 (5): 609–16.
18. Hess A, Buchmann J, Zettl UK, et al. (1999). “Borrelia burgdorferi central nervous system infection presenting as an organic schizophrenia-like disorder”. Biol. Psychiatry 45 (6): 795.
19. Puius YA, Kalish RA (June 2008). “Lyme arthritis: pathogenesis, clinical presentation, and management”. Infect. Dis. Clin. North Am. 22 (2): 289– 300, vi–vii.
20. Mullegger RR (2004). “Dermatological manifestations of Lyme borreliosis”. Eur J Dermatol 14 (5): 296–309.
21. Tilly K, Rosa PA, Stewart PE (June 2008). “Biology of infection with Borrelia burgdorferi”. Infect. Dis. Clin. North Am. 22 (2): 217–34,
22. Lo Re V, Occi JL, MacGregor RR (April 2004). “Identifying the vector of Lyme disease”. Am Fam Physician 69 (8): 1935–7.
23. Steere AC (July 2001). N. Engl. J. Med. 345 (2): 115–25.
24. Puius YA, Kalish RA (June 2008). “Lyme arthritis: pathogenesis, clinical presentation, and management”. Infect. Dis. Clin. North Am. 22 (2): 289–300, vi–vi.
25. Tylewska-Wierzbanowska S, Chmielewski T. (Jul 2002) “Limitation of serological testing for Lyme borreliosis evaluation of ELISA and western blot in comparison with PCR and culture methods”. Wien Klin Wochenschr 114(13- 14):601-5.